Structure-immunogenicity relationships of therapeutic proteins.
about
Immunogenicity of protein therapeutics: The key causes, consequences and challengesProperties, production, and applications of camelid single-domain antibody fragmentsImmunogenicity of Biotherapeutics: Causes and Association with Posttranslational ModificationsThe emergence of biosimilar insulin preparations--a cause for concern?Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applicationsEarly implementation of QbD in biopharmaceutical development: a practical exampleShanghai eye treatment outbreak: bevacizumab therapy for AMD in ChinaConverting the Highly Amyloidogenic Human Calcitonin into a Powerful Fibril Inhibitor by Three-dimensional Structure Homology with a Non-amyloidogenic AnalogueDirected Evolution of Human Heavy Chain Variable Domain (VH) Using In Vivo Protein Fitness FilterMaltose-binding protein fusion allows for high level bacterial expression and purification of bioactive mammalian cytokine derivativesPredicting Hemagglutinin MHC-II Ligand Analogues in Anti-TNFα Biologics: Implications for Immunogenicity of Pharmaceutical ProteinsAnticalins: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies.Comparative testing and pharmacovigilance of biosimilars.In Vivo Analysis of the Potency of Silicone Oil Microdroplets as Immunological Adjuvants in Protein FormulationsSilicone Oil Microdroplets Can Induce Antibody Responses Against Recombinant Murine Growth Hormone in Mice.Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice.Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange.Conformational stability as a design target to control protein aggregation.High-throughput thermal stability analysis of a monoclonal antibody by attenuated total reflection FT-IR spectroscopic imaging.Analytical characterization of a monoclonal antibody therapeutic reveals a three-light chain species that is efficiently removed using hydrophobic interaction chromatography.Understanding the interaction determinants of CAPN1 inhibition by CAST4 from bovines using molecular modeling techniques.Formulation, Delivery and Stability of Bone Morphogenetic Proteins for Effective Bone Regeneration.Evaluation of protein engineering and process optimization approaches to enhance antibody drug manufacturability.Engineered protein A ligands, derived from a histidine-scanning library, facilitate the affinity purification of IgG under mild acidic conditions.Therapeutic protein aggregation: mechanisms, design, and control.Mass spectrometric analysis of intact human monoclonal antibody aggregates fractionated by size-exclusion chromatography.Detection and characterization of subvisible aggregates of monoclonal IgG in serumA platform for characterizing therapeutic monoclonal antibody breakdown products by 2D chromatography and top-down mass spectrometry.Immunogenicity to biologics: mechanisms, prediction and reduction.Multivalent protein polymers with controlled chemical and physical properties.Directed evolution of Her2/neu-binding IgG1-Fc for improved stability and resistance to aggregation by using yeast surface display.Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17-biased T cell responses.Transmission electron microscopy as an orthogonal method to characterize protein aggregates.Sensitive and molecular size-selective detection of proteins using a chip-based and heteroliganded gold nanoisland by localized surface plasmon resonance spectroscopyEmerging patient safety issues under health care reform: follow-on biologics and immunogenicity.Development of a highly stable, nonaqueous glucagon formulation for delivery via infusion pump systemsAnalytical characterization of ch14.18: a mouse-human chimeric disialoganglioside-specific therapeutic antibody.Analytical detection and characterization of biopharmaceutical glycosylation by MS.A 45-Amino-Acid Scaffold Mined from the PDB for High-Affinity Ligand Engineering.Preclinical and clinical in vitro in vivo correlation of an hGH dextran microsphere formulation
P2860
Q24633296-F9AA5560-18B3-4E18-8C08-D0290EDA6286Q24676749-7A27F2E8-0AE9-4988-BFBC-42F8E2603277Q26738810-78FD817C-DA9C-4AE8-AF48-DF01A765BE5FQ26824362-FC9293E8-08F7-4DD8-BC1C-AED682C19BA3Q26824543-A668DB61-BC2F-4A28-A9C8-DE6ADEBCC53DQ26830466-A652C561-2955-4C26-9843-0FE3D4AF1D8EQ27008066-0C747EE2-733F-4EA8-878F-6294D0FB9B43Q27665898-B524514C-C9B0-4D17-BC08-7E75150E86D3Q27684059-B6FB8488-4B02-44B0-BBB3-7BD42C22BF25Q28542860-5ED54151-B938-40F1-B7E1-BA604A2C3C19Q28547255-A1C33B91-8608-4E7F-83C8-5397E938EE03Q30157932-279853D9-9FF4-414C-BF09-2986CA38AFAEQ30356696-8EC79E7B-BA2E-4A98-B44C-E55966D2D4E8Q30376902-699368CF-7C3C-49C3-ACFA-6809EE862796Q30386156-F83AABBD-007F-4D41-8398-95FC2132EB4EQ30402355-74E7B7A9-888F-4DB5-8D33-5800AAF191CEQ30454017-204E7562-2199-4DA2-8AFC-9CFC1FE026F5Q30457837-570E1F22-8718-4AF8-AE2A-1B45F64C0ECBQ30596814-101F6802-64E7-4236-884C-2EEB8A1D1675Q30664490-EE470505-FF2B-4D20-B7D4-73FE2AAFD89EQ33359090-4DD674E1-4675-4EB2-BFA4-C92ED07DECEFQ33639409-7CC1D1E5-160C-4555-A37D-4E3495960FBCQ33913768-0055FEA5-117B-42A5-83DF-89CF5295AFE0Q33936317-FF76ED79-105A-48B7-9D82-700E84110194Q34097620-F40439AB-9EE7-4C7A-8406-8F7B17415FBFQ34127391-1AF3CF3E-C081-47BC-A1C5-D3CBE1B5FAC3Q34216430-E88B5914-05D6-4FB6-BEB7-B73A3EE4C12FQ34267219-6B8C1539-5DF1-4C7E-98F7-5647E1634951Q34296526-4D93AF36-AFE5-4F81-9E32-83F1B7911D7BQ34514739-67EA8B1A-C290-4F88-BF8F-82B89575F100Q34522668-16DC2571-6369-472F-B92A-0A44E50B0D47Q34624117-AA808835-49F3-434E-88C7-C4BA2C47A040Q35224074-050ACF9E-186B-47D2-AD7B-97B141C3A98FQ35537021-199087AB-2D5B-4062-997F-89DECAD0108DQ35660768-A32FCB52-FF91-4C55-8E87-4D7104984598Q35830421-E8B5CC2E-945C-4D28-8C42-F847C64142A6Q35918866-8D961390-67E1-4596-9F88-943B98F4454CQ35953047-1D6600EA-310D-4E84-8D72-F02489DFC8FEQ35954982-9897B7C5-D790-4DBB-B2E1-95E2DBA4FDD8Q36116861-34002044-CBA2-4DF5-832E-766F8DE9C2FB
P2860
Structure-immunogenicity relationships of therapeutic proteins.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Structure-immunogenicity relationships of therapeutic proteins.
@ast
Structure-immunogenicity relationships of therapeutic proteins.
@en
type
label
Structure-immunogenicity relationships of therapeutic proteins.
@ast
Structure-immunogenicity relationships of therapeutic proteins.
@en
prefLabel
Structure-immunogenicity relationships of therapeutic proteins.
@ast
Structure-immunogenicity relationships of therapeutic proteins.
@en
P2093
P1476
Structure-immunogenicity relationships of therapeutic proteins.
@en
P2093
Daan J A Crommelin
Huub Schellekens
Suzanne Hermeling
Wim Jiskoot
P304
P356
10.1023/B:PHAM.0000029275.41323.A6
P577
2004-06-01T00:00:00Z